查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1212587

慢性的阻塞型肺疾(COPD)治療藥的全球市場

Chronic Obstructive Pulmonary Disease (COPD) Treatment
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 299 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

慢性的阻塞型肺疾(COPD)治療藥的全球市場2030年將達到278億美元

在COVID-19後改變的商務環境中，2022年195億美元了的慢性的阻塞型肺疾(COPD)治療藥的全球市場在2030年前將修正達到278億美元的規模，在分析期間2022-2030年間將以4.5％的年複合成長率增長。本報告所分析的市場區隔之一的聯合治療將記錄年複合成長率4.9％，到分析期間結束時將達到159億美元。考慮疫情後的復甦，支氣管擴張劑市場區隔今後8年的年複合成長率將修正為4.3％。

美國市場估算為53億美元，中國預測將以年複合成長率7.6％增長

美國的慢性的阻塞型肺疾(COPD)治療藥市場，2022年53億美元。作為世界第2大經濟大國的中國，在2022年到2030年間年複合成長率將為7.6％在2030年前將修正達到59億美元的市場規模。其他熱門的地區市場有日本和加拿大，從2022年到2030各將以2.3％和3.7％的速度成長。在歐洲市場中，德國以年複合成長率約3％成長。澳洲，印度，韓國等國家推動下的亞太地區市場在2030年前將修正達到37億美元。

調查對像企業範例

  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Chiesi Farmaceutici SpA
  • GlaxoSmithKline PLC
  • Mylan NV
  • Novartis International AG
  • Orion Corporation
  • Sunovion Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

第4章 競爭

簡介目錄
Product Code: MCP-6220

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market to Reach $27.8 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Chronic Obstructive Pulmonary Disease (COPD) Treatment estimated at US$19.5 Billion in the year 2022, is projected to reach a revised size of US$27.8 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2022-2030. Combination, one of the segments analyzed in the report, is projected to record a 4.9% CAGR and reach US$15.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Bronchodilators segment is readjusted to a revised 4.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $5.3 Billion, While China is Forecast to Grow at 7.6% CAGR

The Chronic Obstructive Pulmonary Disease (COPD) Treatment market in the U.S. is estimated at US$5.3 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.9 Billion by the year 2030 trailing a CAGR of 7.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.3% and 3.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3.7 Billion by the year 2030.

Select Competitors (Total 53 Featured):

  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Chiesi Farmaceutici SpA
  • GlaxoSmithKline PLC
  • Mylan NV
  • Novartis International AG
  • Orion Corporation
  • Sunovion Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Chronic Obstructive Pulmonary Disease Treatment - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 3: World 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Bronchodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Bronchodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 6: World 18-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 9: World 18-Year Perspective for Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Phosphodiesterase Type 4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Phosphodiesterase Type 4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 12: World 18-Year Perspective for Phosphodiesterase Type 4 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Mucokinetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Mucokinetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 15: World 18-Year Perspective for Mucokinetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 18: World 18-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 21: World 18-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 22: World Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 25: USA 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 28: Canada 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • JAPAN
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 31: Japan 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • CHINA
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: China Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 34: China 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • EUROPE
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 37: Europe 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 40: Europe 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • FRANCE
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 41: France Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: France Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 43: France 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • GERMANY
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Germany Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 46: Germany 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • ITALY
    • TABLE 47: Italy Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Italy Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 49: Italy 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • UNITED KINGDOM
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: UK Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 52: UK 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • SPAIN
    • TABLE 53: Spain Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Spain Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 55: Spain 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • RUSSIA
    • TABLE 56: Russia Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Russia Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 58: Russia 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • REST OF EUROPE
    • TABLE 59: Rest of Europe Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Rest of Europe Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 61: Rest of Europe 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • ASIA-PACIFIC
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 64: Asia-Pacific 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
    • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Asia-Pacific Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 67: Asia-Pacific 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • AUSTRALIA
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 68: Australia Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Australia Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 70: Australia 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • INDIA
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 71: India Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: India Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 73: India 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • SOUTH KOREA
    • TABLE 74: South Korea Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: South Korea Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 76: South Korea 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 77: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Rest of Asia-Pacific Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 79: Rest of Asia-Pacific 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • LATIN AMERICA
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 82: Latin America 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2023 & 2030
    • TABLE 83: Latin America Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Latin America Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 85: Latin America 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • ARGENTINA
    • TABLE 86: Argentina Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Argentina Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 88: Argentina 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • BRAZIL
    • TABLE 89: Brazil Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Brazil Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 91: Brazil 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • MEXICO
    • TABLE 92: Mexico Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Mexico Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 94: Mexico 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 95: Rest of Latin America Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Rest of Latin America Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 97: Rest of Latin America 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • MIDDLE EAST
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 100: Middle East 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2023 & 2030
    • TABLE 101: Middle East Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Middle East Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 103: Middle East 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • IRAN
    • TABLE 104: Iran Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Iran Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 106: Iran 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • ISRAEL
    • TABLE 107: Israel Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Israel Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 109: Israel 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 110: Saudi Arabia Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Saudi Arabia Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 112: Saudi Arabia 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 113: UAE Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: UAE Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 115: UAE 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 116: Rest of Middle East Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Rest of Middle East Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 118: Rest of Middle East 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030
  • AFRICA
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 119: Africa Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: Africa Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 121: Africa 18-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2012, 2023 & 2030

IV. COMPETITION